Abstract: Objective To explore the clinical efficacy of levosimendan combined with conventional anti-heart failure drugs in the treatment of refractory heart failure. Methods A total of 84 patients with refractory heart failure who were hospitalized in the cardiovascular department of our hospital were randomly divided into control group and study group, with 42 cases in each group. The control group was given conventional anti-heart failure drugs, while the study group was additionally treated with levosimendan on the basis of the control group. Before and after treatment, changes in indicators of cardiac ultrasound examination, serum N-terminal pronatriuretic peptide(NT-proBNP), cardiac troponin T(cTnT)and hypersensitive C reactive protein(hs-CRP)levels were compared between the two groups, and short-term efficacy of two groups was compared. Results Left ventricular ejection fraction(LVEF), stroke volume(SV)and cardiac index(CI)in the two groups were significantly higher(P<0.05), and LVEF, SV and CI in the study group were higher than those in the control group(P<0.05). The levels of NT-proBNP, cTnT and hs-CRP in the two groups were significantly lower than those before treatment(P<0.05), and the study group was significantly lower than the control group(P<0.05). The total clinical effective rate of the study group and the control group were 92.86% and 76.19%, respectively, which showed a significant difference(P<0.05). Conclusion Levosimendan combined with conventional anti-heart failure drugs can significantly improve the heart function of patients with refractory heart failure, reduce myocardial injury and inflammatory response, and increase the clinical efficacy.